Author: Jose Maria Ruiz Moreno (Spain)
Co-authors: Luis Arias Barquet, Laia Gómez-Baldó, José García-Arumí
To evaluate the impact of age-related macular degeneration (AMD) on health-related quality of life (QoL) and daily activities from the patients' perspective.
Patients diagnosed with AMD (dry AMD [dAMD] or neovascular AMD [nAMD]) who voluntarily decided to contact to participate in a telephone interview, between August 29th, 2019 and February 28th, 2020 in Spain.
Observational, non-interventional, cross-sectional study in Spain. Patients ≥50 years AMD diagnosed (dAMD or nAMD) who voluntarily contacted to answer to a telephone interview. Patients were informed about the study from patients’ associations, pensioners' organizations, online advertisements, or informative leaflets available in hospital centers. Six-month data collection period.
181 evaluable patients: 44.9% dAMD and 55.1% nAMD. Mean (standard deviation, SD) age of 72.5 (8.9) years, mainly females (59.1%), living in company (81.2%). 79.0% suffered concomitant diseases: most prevalent osteoarthrosis (37.8%), diabetes (30.1%) and hypertension (26.6%). At diagnosis, 11.6% showed poor/very poor vision; 69.6% reported fear of going blind. 63.2% stopped driving and 33.7% reported having less control over their daily routine due to their vision. Mean (SD) time from first complaints to AMD diagnosis was 6.4 (14.5) months and 2.9 (6.8) months from diagnosis to first treatment. Most frequent visual symptoms were blurred vision in the center of the visual field (76.2%) and alteration in the shape of the images (38.7%). Greatest limitations were observed in daily living activities in environments unknown to the patient: use of public transport in new routes (32.0%), mobility in unknown places/paths (31.0%) and attending to a medical appointment (27.6%). Therefore, 48.8% of the patients needed support from a caregiver to perform domestic/housekeeping tasks and accompanying, while 13.9% needed support from domestic employees (mostly payed by patients or their families). AMD showed a great impact on patient's self-confidence/security (44.2%), in their mood (39.7%) and anxiety/nervousness (36.5%), with greater psychological impact in nAMD patients.
The loss of vision in AMD patients is important, having a relevant impact on health-related QoL in aspects directly associated with the vision loss or psychological affectation. Furthermore, the dependence of these patients generates significant indirect costs. Preservation of vision is critical to limit the AMD impact on patient’s life.
José María Ruiz-Moreno: Advisory board of Allergan, Bayer, Novartis, and Topcon Luis Arias Barquet: Advisor for Allergan, Bayer, Novartis, Roche, and Topcon Laia Gómez-Baldó: Employee of Novartis José García-Arumí: Advisory board of Novartis, Bayer, and Alcon